Andrew J. Muir

18.3k total citations · 7 hit papers
213 papers, 11.2k citations indexed

About

Andrew J. Muir is a scholar working on Hepatology, Epidemiology and Surgery. According to data from OpenAlex, Andrew J. Muir has authored 213 papers receiving a total of 11.2k indexed citations (citations by other indexed papers that have themselves been cited), including 163 papers in Hepatology, 131 papers in Epidemiology and 32 papers in Surgery. Recurrent topics in Andrew J. Muir's work include Liver Disease Diagnosis and Treatment (115 papers), Hepatitis C virus research (106 papers) and Hepatitis B Virus Studies (43 papers). Andrew J. Muir is often cited by papers focused on Liver Disease Diagnosis and Treatment (115 papers), Hepatitis C virus research (106 papers) and Hepatitis B Virus Studies (43 papers). Andrew J. Muir collaborates with scholars based in United States, United Kingdom and Canada. Andrew J. Muir's co-authors include John G. McHutchison, Mark Sulkowski, Alexander Thompson, Thomas Urban, Ping Qiu, Jacques Fellay, Dongliang Ge, Arthur H. Bertelsen, Kevin V. Shianna and David B. Goldstein and has published in prestigious journals such as Nature, New England Journal of Medicine and JAMA.

In The Last Decade

Andrew J. Muir

203 papers receiving 11.0k citations

Hit Papers

Genetic variation in IL28B predicts hepatitis C treatment... 2008 2026 2014 2020 2009 2009 2009 2008 2019 500 1000 1.5k 2.0k 2.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
    2009 2.6k citations Alexander Thompson, Andrew J. Muir et al. profile →
  2. Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection
    2009 889 citations John G. McHutchison, Eric Lawitz et al. profile →
  3. Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection
    2009 803 citations John G. McHutchison, Stuart C. Gordon et al. profile →
  4. Modification and validation of the Birmingham Vasculitis Activity Score (version 3)
    2008 794 citations Andrew J. Muir et al. profile →
  5. The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials
    2019 255 citations Arun J. Sanyal, Stephen A. Harrison et al. Hepatology profile →
  6. The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS‐9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis
    2019 205 citations Michael Trauner, Aliya Gulamhusein et al. Hepatology profile →
  7. Primary sclerosing cholangitis
    2025 13 citations Michael P. Manns, Cynthia Levy et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Andrew J. Muir United States 41 8.1k 7.3k 1.4k 1.0k 1.0k 213 11.2k
Karen L. Lindsay United States 52 9.5k 1.2× 9.0k 1.2× 1.1k 0.8× 793 0.8× 643 0.6× 150 12.9k
Jenny Heathcote Canada 53 10.0k 1.2× 9.9k 1.3× 954 0.7× 843 0.8× 1.7k 1.7× 175 12.6k
Yasuji Arase Japan 52 9.1k 1.1× 8.7k 1.2× 714 0.5× 873 0.9× 726 0.7× 394 11.6k
Wan‐Long Chuang Taiwan 53 8.5k 1.0× 8.3k 1.1× 616 0.4× 733 0.7× 732 0.7× 513 11.1k
Ming‐Lung Yu Taiwan 53 7.4k 0.9× 7.7k 1.0× 614 0.4× 707 0.7× 744 0.7× 490 10.8k
Vinod K. Rustgi United States 35 11.9k 1.5× 10.7k 1.5× 1.2k 0.9× 1.6k 1.6× 690 0.7× 173 13.8k
Pietro Andreoné Italy 49 7.7k 0.9× 7.1k 1.0× 359 0.3× 824 0.8× 1.3k 1.3× 346 9.9k
Ira M. Jacobson United States 64 17.0k 2.1× 15.7k 2.1× 1.5k 1.1× 3.0k 2.9× 962 1.0× 338 19.9k
Francesco Negro Switzerland 64 12.4k 1.5× 12.2k 1.7× 1.0k 0.7× 1.5k 1.4× 823 0.8× 311 16.0k
Robert G. Gish United States 68 12.4k 1.5× 12.4k 1.7× 431 0.3× 1.7k 1.7× 1.8k 1.8× 373 16.0k

Countries citing papers authored by Andrew J. Muir

Since Specialization
Citations

This map shows the geographic impact of Andrew J. Muir's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew J. Muir with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew J. Muir more than expected).

Fields of papers citing papers by Andrew J. Muir

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew J. Muir. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew J. Muir. The network helps show where Andrew J. Muir may publish in the future.

Co-authorship network of co-authors of Andrew J. Muir

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew J. Muir. A scholar is included among the top collaborators of Andrew J. Muir based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew J. Muir. Andrew J. Muir is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sanyal, Arun J., Quentin M. Anstee, Michael Trauner, et al.. (2021). Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis. Hepatology. 75(5). 1235–1246. 89 indexed citations
2.
Younossi, Zobair M., Andrei Racila, Andrew J. Muir, et al.. (2021). Long-term Patient-Centered Outcomes in Cirrhotic Patients With Chronic Hepatitis C After Achieving Sustained Virologic Response. Clinical Gastroenterology and Hepatology. 20(2). 438–446. 10 indexed citations
3.
Patel, Yuval A., et al.. (2020). Reduced Alcohol Use Is Sustained in Patients Provided Alcohol-Related Counseling During Direct-Acting Antiviral Therapy for Hepatitis C. Digestive Diseases and Sciences. 66(9). 2956–2963. 3 indexed citations
4.
Trivedi, Palak, Andrew J. Muir, Cynthia Levy, et al.. (2020). Inter- and Intra-individual Variation, and Limited Prognostic Utility, of Serum Alkaline Phosphatase in a Trial of Patients With Primary Sclerosing Cholangitis. Clinical Gastroenterology and Hepatology. 19(6). 1248–1257. 34 indexed citations
5.
6.
Trauner, Michael, Aliya Gulamhusein, Bilal Hameed, et al.. (2019). The nonsteroidal FXR agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with PSC.. Hepatology. 3 indexed citations
7.
Trauner, Michael, Yevgeniy Gindin, Zhaoshi Jiang, et al.. (2019). Methylation signatures in peripheral blood are associated with marked age acceleration and disease progression in patients with primary sclerosing cholangitis. JHEP Reports. 2(1). 100060–100060. 14 indexed citations
8.
Patel, Yuval A., Jacqueline B. Henson, Julius Wilder, et al.. (2018). The impact of human leukocyte antigen donor and recipient serotyping and matching on liver transplant graft failure in primary sclerosing cholangitis, autoimmune hepatitis, and primary biliary cholangitis. Clinical Transplantation. 32(10). e13388–e13388. 9 indexed citations
9.
Proeschold‐Bell, Rae Jean, Donna M. Evon, Christina Makarushka, et al.. (2018). The Hepatitis C-Alcohol Reduction Treatment (Hep ART) intervention: Study protocol of a multi-center randomized controlled trial. Contemporary Clinical Trials. 72. 73–85. 8 indexed citations
10.
Jou, Janice H. & Andrew J. Muir. (2017). Hepatocellular Carcinoma Surveillance. Clinical Gastroenterology and Hepatology. 16(1). 19–20. 8 indexed citations
11.
Patel, Yuval A. & Andrew J. Muir. (2016). Evaluation of New-Onset Ascites. JAMA. 316(3). 340–340. 10 indexed citations
12.
Bowlus, Christopher L., Kalpesh Patel, Indra Neil Guha, et al.. (2015). Validation of serum fibrosis marker panels in patients with primary sclerosing cholangitis (PSC) in a randomized trial of simtuzumab. Hepatology. 62. 2 indexed citations
13.
14.
Muir, Andrew J., et al.. (2014). P774 CLINICAL IMPACT OF AN INTERNET-BASED TOOL TO HELP GUIDE TIMING OF HCV THERAPY. Journal of Hepatology. 60(1). S328–S328. 1 indexed citations
15.
Norton, Brianna L., et al.. (2012). Health Care Utilization in HIV-Infected Patients: Assessing the Burden of Hepatitis C Virus Coinfection. AIDS Patient Care and STDs. 26(9). 541–545. 23 indexed citations
16.
Naggie, Susanna, Anu Osinusi, Antonios Katsounas, et al.. (2012). Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B -unfavorable genotype patients: Impaired viral kinetics and therapeutic response. Hepatology. 56(2). 444–454. 55 indexed citations
17.
Clark, Paul J., Alexander Thompson, Stuart C. Gordon, et al.. (2011). PREDICTORS OF CONSENT TO PHARMACOGENOMICS TESTING IN THE IDEAL STUDY. Hepatology. 54.
18.
Thompson, Alexander, Paul J. Clark, Hans L. Tillmann, et al.. (2011). Il28B C/c Genotype Is Predictive of >= 1 Log10 Iu/ml Reduction in Plasma Hcv Rna After 4 Weeks of Peginterferon (Pegifn) and Ribavirin (Rbv) Therapy: Implications for the Use of the Lead-In Strategy for Direct-Acting Antiviral-Based Treatment Regimens. Hepatology. 54. 3 indexed citations
19.
Clark, Paul J., et al.. (2011). Vitamin D and Treatment Response in African American Patients with Hcv Genotype 1. Hepatology. 54. 5 indexed citations
20.
Muir, Andrew J., Linda Sanders, William E. Wilkinson, & Kenneth E. Schmader. (2001). Reducing medication regimen complexity. Journal of General Internal Medicine. 16(2). 77–82. 94 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Karen L. Lindsay Breakdown of academic impact, for papers by Jenny Heathcote Breakdown of academic impact, for papers by Yasuji Arase Breakdown of academic impact, for papers by Wan‐Long Chuang Breakdown of academic impact, for papers by Ming‐Lung Yu Breakdown of academic impact, for papers by Vinod K. Rustgi Breakdown of academic impact, for papers by Pietro Andreoné Breakdown of academic impact, for papers by Ira M. Jacobson Breakdown of academic impact, for papers by Francesco Negro Breakdown of academic impact, for papers by Robert G. Gish
Rankless by CCL
2026